4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up Following Analyst Upgrade

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Contrasting NLS Pharmaceutics (NASDAQ:NCEL) and 4D Molecular Therapeutics (NASDAQ:FDMT)

4DMT Provides Company Update and Anticipated Development Milestones for 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,821.50 in Stock

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

4DMT Announces New Employment Inducement Grants

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

4DMT to Participate in 8th Annual Evercore Healthcare Conference

4DMT Appoints Kristian Humer as Chief Financial Officer

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Jefferies 2025 London Healthcare Conference

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4DMT Announces New Employment Inducement Grants

Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors